Home » AGEB Journal » Issues » Volume 83" » Fasc.1 - Reviews » Article details

Posterior reversible encephalopathy syndrome secondary to oxaliplatin-based chemotherapy and regorafenib in metastastic colorectal cancer : case reports and literature review

Journal Volume 83 - 2020
Issue Fasc.1 - Reviews
Author(s) Q. Van Pelt 1, E. Stragier 1, P. Roelandt 1, E. Van Cutsem 1
Full article
Full Article
PAGES 47-50
VIEW FREE PDF
Affiliations:
(1) Digestive Oncology Department, University Hospitals Leuven, Belgium

Posterior reversible encephalopathy syndrome (PRES) is a rare disorder with multiple causes but potentially caused by chemotherapy. We present 3 cases of PRES of whom 2 are presumably caused by oxaliplatin and one by regorafenib. We discuss in this article the 3 cases individually and we summarize in the discussion the proposed theories in the literature of possible pathophysiological mechanisms. Our main goal of this article is to increase awareness among physicians when they are confronted with patients on chemotherapy who present with (sub)acute encephalopathy. (Acta gastroenterol. belg., 2020, 83, 47-50).

Keywords: colorectal cancer, encephalopathy, regorafenib, oxaliplatin.

The authors declare that they have no conflict of interest.
© Acta Gastro-Enterologica Belgica.
PMID 32233271